Research program Live corpus

Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.

PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,405 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

Explore Platform → See latest papers

40,405 Papers indexed

1,440 Papers AI scored

40,405 Ranked papers

100.0% Coverage

Featured discovery ● Live

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

AI Score 79.80 Active signal

Grade A

Final score 88.16

Narrative velocity Not calculated

Confidence Building

CHIP-AML22 is a multinational pediatric de novo AML trial protocol integrating risk-adapted therapy, randomized gemtuzumab ozogamicin and consolidation-course comparisons, subgroup-specific quizartinib, and toxicity-reduction measures.

Read full analysis →

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE

↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing

TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Published Jun 20, 2026

Journal Trials

88.16 Ranking score

A grade PMID 42321916

View analysis →

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Published Sep 03, 2026

Journal JAMA oncology

87.88 Ranking score

A grade PMID 42690647

View analysis →

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Published Jul 01, 2026

Journal The Lancet. Oncology

87.73 Ranking score

A grade PMID 42372741

View analysis →

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.

Published May 30, 2026

Journal Oncoimmunology

87.38 Ranking score

A grade PMID 42216567

View analysis →

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Published Mar 31, 2026

Journal BMJ (Clinical research ed.)

87.15 Ranking score

A grade PMID 41916649

View analysis →

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Published May 18, 2026

Journal EClinicalMedicine

86.97 Ranking score

A grade PMID 42382416

View analysis →

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Published May 18, 2026

Journal The Lancet. Child & adolescent health

85.99 Ranking score

A grade PMID 42150584

View analysis →

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

Published Sep 17, 2026

Journal The New England journal of medicine

85.54 Ranking score

B grade PMID 42748428

View analysis →

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.

Published Feb 20, 2026

Journal bioRxiv : the preprint server for biology

85.22 Ranking score

A grade PMID 41756844

View analysis →

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Published Sep 21, 2026

Journal Blood cancer discovery

85.08 Ranking score

A grade PMID 42765973

View analysis →

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Published Jun 26, 2026

Journal Cancer letters

85.07 Ranking score

A grade PMID 42362103

View analysis →

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Published Jul 14, 2026

Journal Blood advances

84.86 Ranking score

A grade PMID 42101908

View analysis →

LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-13 10:15 AM

1 Interventions to reduce paediatric cancer treatment abandonment in low-income and middle-income countries: a systematic review and meta-analysis. The Lancet. Global health — Nov 13, 2026 2 Paediatric cancer treatment abandonment: multifaceted solutions required. The Lancet. Global health — Nov 13, 2026 3 Enteral Clonidine for the Management of Rigors in Pediatric Oncology. Journal of palliative medicine — Nov 13, 2026 4 Real-world implementation of optic pathway glioma surveillance in children with neurofibromatosis type 1: a 20-year cohort study. The British journal of ophthalmology — Nov 13, 2026 5 Pediatric-type Follicular Lymphoma Shows Unique Immunogenetic Features With Lack of Acquired N-glycosylation Sites. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc — Nov 13, 2026 6 Epigenetic Divergence Distinguishes Molecularly and Histologically Distinct Subtypes of Small Cell Carcinoma of the Ovary Hypercalcemic Type. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc — Nov 13, 2026 7 Radiation in Spine Care: A Comprehensive Review of Radiation Sources, Emerging Technology, Cancer Risk, and Radiation Stewardship. The spine journal : official journal of the North American Spine Society — Nov 13, 2026 8 Polycyclic Aromatic Hydrocarbons in Urban Motor-Park Soils of Asaba, Nigeria: Environmental Contamination, Source Characterization, and Human Health Risk. Environmental pollution (Barking, Essex : 1987) — Nov 13, 2026

WHAT THE AI SEES TODAY

Live pediatric oncology intelligence

● Live

↗

Therapeutic signal strength is updating across newly scored pediatric oncology literature.

✦

Mechanism clusters are forming around tumor biology, immune response, targeted therapy, treatment resistance, and drug repurposing.

⌁

Daily literature intake feeds the ranking engine and refreshes study-design, human-relevance, and therapeutic-relevance scores.

●

40,405 pediatric cancer records are currently visible under this search.

PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40405 results

Letter From Malaysia: Advancing Respiratory Frontiers Through Innovation, Education, and Collaboration.

PMID 40730490 Published: 2025-07-29 Ingested: 2026-08-02 12:04 AM Respirology (Carlton, Vic.)

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Abnormal Arm Movements as the Presenting Sign of a Childhood Spinal Cord Tumor.

PMID 40696980 Published: 2025-07-23 Ingested: 2026-08-02 12:04 AM Journal of child neurology

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Hemolysis and Acquired Pyruvate Kinase Deficiency in a Child With a Malignant Myeloid Disorder.

PMID 40657857 Published: 2025-07-14 Ingested: 2026-08-02 12:04 AM American journal of hematology

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Anesthetic management of neuroblastoma excision in child with Kinsbourne syndrome.

PMID 40635845 Published: 2025-04-10 Ingested: 2026-08-02 12:04 AM Journal of anaesthesiology, clinical pharmacology

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Intraventricular mass in a 49-year-old male.

PMID 40610013 Published: 2025-07-03 Ingested: 2026-08-02 12:04 AM Brain pathology (Zurich, Switzerland)

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Pleomorphic xanthoastrocytoma with anaplasia and BEND5-NTRK2 fusion in a young adult with a history of cranial radiation for childhood rhabdomyosarcoma.

PMID 40568680 Published: 2025-03-08 Ingested: 2026-08-02 12:03 AM Neuro-oncology advances

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Indurated Plaques in an Otherwise Healthy Child.

PMID 40528509 Published: 2025-06-18 Ingested: 2026-08-02 12:04 AM Pediatric dermatology

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply.

PMID 40499182 Published: 2025-06-12 Ingested: 2026-08-02 12:04 AM The New England journal of medicine

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia.

PMID 40499181 Published: 2025-06-12 Ingested: 2026-08-02 12:04 AM The New England journal of medicine

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Anti-NMDA receptor encephalitis in a child with H3K27M mutant pontine diffuse midline glioma.

PMID 40473322 Published: 2025-06-04 Ingested: 2026-08-02 12:04 AM BMJ case reports

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Causes of subsequent neoplasms after childhood cancer.

PMID 40449492 Published: 2025-06-01 Ingested: 2026-08-02 12:04 AM The Lancet. Oncology

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Neuroimaging and Metabolic Features of Optic Pathway Glioma in a Child with Neurofibromatosis Type 1: Low-Grade Glioma Transformation in the Left Optic Radiation.

PMID 40436391 Published: 2025-05-28 Ingested: 2026-08-02 12:04 AM RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin

AI -

Standard 27.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 27.5/100. Study design: 25.0; human relevance: 35.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Page 3357 of 3368

Open the Research
Intelligence Map

Finding therapies hidden in 40,405 pediatric cancer papers.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Ranked Discovery Journal Articles

Database feed

All ranked pediatric cancer papers

AI-assisted research information

Open the Research Intelligence Map